Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

ClinicalTrials.gov ID: NCT00794586

Public ClinicalTrials.gov record NCT00794586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa

Study identification

NCT ID: NCT00794586
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Gilead Sciences; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Cystic Fibrosis

Interventions

FTI, AZLI Drug
Placebo, AZLI Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2008
Primary completion: Jan 31, 2010
Completion: Feb 28, 2010
Last update posted: Dec 26, 2013

2008 – 2010

United States locations

U.S. sites: 36
U.S. states: 21
U.S. cities: 35

Facility	City	State	ZIP	Site status
Not listed	Anchorage	Alaska	99508	—
Not listed	Phoenix	Arizona	85016	—
Not listed	Tucson	Arizona	85724	—
Not listed	Little Rock	Arkansas	72205	—
Not listed	Palo Alto	California	94304	—
Not listed	Denver	Colorado	80206	—
Not listed	Hartford	Connecticut	06102	—
Not listed	New Haven	Connecticut	06520	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Orlando	Florida	32803	—
Not listed	Tampa	Florida	33606	—
Not listed	Chicago	Illinois	60614	—
Not listed	Glenview	Illinois	60025	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Detroit	Michigan	48201	—
Not listed	Las Vegas	Nevada	89107	—
Not listed	Albany	New York	12208	—
Not listed	Buffalo	New York	14222	—
Not listed	New Hyde Park	New York	11040	—
Not listed	New York	New York	10032	—
Not listed	Syracuse	New York	13210	—
Not listed	Chapel Hill	North Carolina	27599	—
Not listed	Cincinnati	Ohio	45229	—
Not listed	Cleveland	Ohio	44106	—
Not listed	Columbus	Ohio	43205	—
Not listed	Oklahoma City	Oklahoma	73112	—
Not listed	Hershey	Pennsylvania	17033	—
Not listed	Philadelphia	Pennsylvania	19102	—
Not listed	Charleston	South Carolina	29425	—
Not listed	Houston	Texas	77030	—
Not listed	San Antonio	Texas	78212	—
Not listed	Portsmouth	Virginia	23708	—
Not listed	Richmond	Virginia	23298	—
Not listed	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00794586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 26, 2013 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00794586 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →